Zydus Saroglitazar Tablets Bilypsa

About Zydus Saroglitazar Tablets Bilypsa

Bilypsa Tablets contain Saroglitazar, a novel dual PPAR- and PPAR- agonist, widely prescribed for the management of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) associated with metabolic disorders. It helps improve liver health by reducing triglycerides, improving insulin sensitivity, and lowering liver enzyme levels.

Bilypsa is also effective in managing diabetic dyslipidemia, making it a preferred choice among physicians for patients with type 2 diabetes and abnormal lipid profiles.

• Helps in management of NAFLD / NASH

• Reduces triglycerides and liver fat

• Improves insulin sensitivity

• Lowers ALT and AST liver enzymes

• Supports overall metabolic and liver health

• Non-Alcoholic Fatty Liver Disease (NAFLD)

• Non-Alcoholic Steatohepatitis (NASH)

• Diabetic Dyslipidemia

• Type 2 Diabetes with lipid abnormalities

As directed by the physician. Usually taken once daily.

Strip / Box packing (as per availability)

Store in a cool, dry place. Protect from moisture and direct sunlight.